Search Results - "Riesen, W. F."

Short-term effects of atorvastatin on C-reactive protein by Riesen, W.F., Engler, H., Risch, M., Korte, W., Noseda, G.

“…Aim To study the short-term effect of atorvastatin on C-reactive protein (CRP) in patients with or at risk for coronary heart disease. Methods and Results One…”
Get full text

Procollagen type I N-propeptide is a predictor of skeletal morbidity in patients with malignant osteolytic bone disease on bisphosphonates by Joerger, M., Templeton, A., Köberle, D., Engler, H., Riesen, W. F., Thürlimann, B.

“…Background There is an urgent need for individualized treatment of malignant bone disease (MBD), as the clinical benefit from bone-targeted therapies is…”
Get full text

Hypertriglyceridemia as a possible risk factor for prostate cancer by Wuermli, L, Joerger, M, Henz, S, Schmid, H-P, Riesen, W F, Thomas, G, Krek, W, Cerny, T, Gillessen, S

“…We retrospectively studied anthropometric and laboratory parameters (including serum triglycerides, cholesterol), as well as comedication in 504 patients…”
Get full text

Bevacizumab-associated hyperlipoproteinemia type IIb in a patient with advanced invasive-ductal breast cancer by Joerger, M, Riesen, WF, Thürlimann, B

“…Aim: We report a case of bevacizumab-associated hyperlipoproteinemia in a patient with advanced breast cancer. Case summary: A 57-year-old woman with advanced…”
Get full text

Effect of thyroid function on concentrations of lipoprotein(a) by Engler, H, Riesen, W F

“…The effect of thyroid hormones on concentrations of lipoprotein(a) [Lp(a)] was analyzed in 60 patients with active thyroid dysfunction (hyperthyroidism 30…”
Get more information

Insulin-like growth factor-I improves glucose and lipid metabolism in type 2 diabetes mellitus by ZENOBI, P. D, JAEGGI-GROISMAN, S. E, RIESEN, W. F, RØDER, M. E, FROESCH, E. R

“…Hyperglycemia, hyperinsulinemia, and insulin resistance cause vascular disease in type 2 diabetes mellitus. Dietary treatment alone often fails and oral drugs…”
Get full text

Comparison of Bezafibrate and Simvastatin in the Treatment of Dyslipidaemia in Patients with NIDDM by Jeck, T., Riesen, W.F., Keller, U.

“…Fibrates and HMG CoA reductase inhibitors are commonly used in the treatment of diabetic dyslipidaemia. However, these two groups of drugs have not been…”
Get full text

Biochemical markers of bone turnover in patients with thyroid dysfunctions and in euthyroid controls: a cross-sectional study by Engler, Hanna, Oettli, René E, Riesen, Walter F

“…Hyperthyroidism is associated with reduced bone mineral density. Conflicting data exist regarding the effects of thyroxine therapy on bone metabolism. The aim…”
Get full text

Comparability of serum and plasma concentrations of haemostasis activation markers by Korte, W, Riesen, W F

“…Since serum and plasma D-dimer concentrations correlate very well, we evaluated the comparability of other haemostasis activation markers in plasma and serum…”
Get more information

Improvement of lipid profile in Type 2 (non-insulin-dependent) diabetes mellitus by insulin-like growth factor I by ZENOBI, P. D, HOLZMANN, P, GLATZ, Y, RIESEN, W. F, FROESCH, E. R

“…Type 2 (non-insulin-dependent) diabetes mellitus is associated with increased glucose, insulin, total and VLDL-triglyceride, and often total and…”
Get full text

Beneficial metabolic effects of insulin-like growth factor I in patients with severe insulin-resistant diabetes type A by Zenobi, P D, Glatz, Y, Keller, A, Graf, S, Jaeggi-Groisman, S E, Riesen, W F, Schoenle, E J, Froesch, E R

“…Severe insulin resistance type A is due to mutations in the insulin receptor gene and is characterized by glucose intolerance or diabetes mellitus, despite…”
Get more information

Anti-thyroid peroxidase (anti-TPO) antibodies in thyroid diseases, non-thyroidal illness and controls. Clinical validity of a new commercial method for detection of anti-TPO (thyroid microsomal) autoantibodies by Engler, H, Riesen, W F, Keller, B

“…The identification of the thyroid peroxidase (TPO) as the main antigen of the thyroid microsomal fraction has enabled the development of a sensitive and…”
Get more information

Effect of thyroid hormones on Lp(a) and lipid metabolism by Engler, H, Riesen, W F

“…The effect of thyroid hormones on lipoprotein(a) plasma concentrations and the other parameters of lipoprotein metabolism was studied in 158 patients with…”
Get more information

High prevalence of cardiovascular risk factors in the Seychelles (Indian Ocean) by Bovet, P, Shamlaye, C, Kitua, A, Riesen, W F, Paccaud, F, Darioli, R

“…In recent years, increasingly high rates of cardiovascular diseases have been recorded in the Seychelles. A survey was performed to investigate the prevalence…”
Get full text

Diagnostic and prognostic value of biochemical markers in malignant bone disease: a prospective study on the effect of bisphosphonate on pain intensity and progression of malignant bone disease by Engler, H, Koeberle, D, Thuerlimann, B, Senn, H J, Riesen, W F

“…Seventy cancer patients with malignant osteolytic bone disease received pamidronate every three weeks for a maximum of six cycles. Bone resorption parameters,…”
Get more information

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) by Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., Graham, I. M., Halliday, A., Landmesser, U., Mihaylova, B., Pedersen, T. R., Riccardi, G., Richter, D. J., Sabatine, M. S., Taskinen, M. R., Tokgozoglu, L., Wiklund, Olov, Mueller, C., Drexel, H., Aboyans, V., Corsini, A., Doehner, W., Farnier, M., Gigante, B., Kayikcioglu, M., Krstacic, G., Lambrinou, E., Lewis, B. S., Masip, J., Moulin, P., Petersen, S., Petronio, A. S., Piepoli, M. F., Pinto, X., Raber, L., Ray, K. K., Reiner, Z., Riesen, W. F., Roffi, M., Schmid, J. P., Shlyakhto, E., Simpson, I. A., Stroes, E., Sudano, I., Tselepis, A. D., Viigimaa, M., Vindis, C., Vonbank, A., Vrablik, M., Vrsalovic, M., Gomez, J. L. Z., Collet, J. P.

Get full text

Multicenter evaluation of Reflotron direct dry-chemistry assay of high-density lipoprotein cholesterol in venous and fingerstick specimens by Warnick, G R, Boerma, G J, Assmann, G, Endler, A T, Gerique, G, Gotto, A M, Graziani, M S, Lippi, U, Patsch, W, Riesen, W F

“…The Reflotron HDL Cholesterol test (Boehringer Mannheim GmbH) directly separates and analyzes high-density lipoprotein (HDL) cholesterol in plasma collected…”
Get more information

Effects of simvastatin and fenofibrate on serum lipoproteins and apolipoproteins in primary hypercholesterolaemia by STOHLER, R, KELLER, U, RIESEN, W. F

“…Sixteen patients with primary hypercholesterolaemia received double-blind either fenofibrate (n = 8; 200 mg bid) or the HMG-CoA reductase inhibitor simvastatin…”
Get full text

Therapeutic efficacy of the HMG-CoA-reductase inhibitor pravastatin in hyperlipoproteinaemia type II by SAXENHOFER, H, WEIDMANN, P, RIESEN, W. F, BERETTA-PICCOLI, C, FRAGIACOMO, C, WUNDERLIN, R, NOSEDA, G

“…The efficacy and safety of the HMG-CoA-reductase inhibitor pravastatin was assessed in a double-blind, placebo controlled study. Thirty patients (51 y) with…”
Get full text

Effects of long-term, self-monitored exercise on the serum lipoprotein and apolipoprotein profile in middle-aged men by Marti, B, Suter, E, Riesen, W F, Tschopp, A, Wanner, H U, Gutzwiller, F

“…To study the effects of long-term, self-monitored exercise on the serum lipid profile and body composition of middle-aged non-smoking males, a controlled study…”
Get more information